APA

Van Cutsem E., Dirix L., Van Laethem J., Van Belle S., Borner M., Gonzalez Baron M., Roth A., Morant R., Joosens E., Gruia G., Sibaud D. & Bleiberg H. (20050428). Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. : British journal of cancer.

Chicago

Van Cutsem E, Dirix L, Van Laethem J-L, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D and Bleiberg H. 20050428. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. : British journal of cancer.

Harvard

Van Cutsem E., Dirix L., Van Laethem J., Van Belle S., Borner M., Gonzalez Baron M., Roth A., Morant R., Joosens E., Gruia G., Sibaud D. and Bleiberg H. (20050428). Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. : British journal of cancer.

MLA

Van Cutsem E, Dirix L, Van Laethem J-L, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D and Bleiberg H. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. : British journal of cancer. 20050428.